1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,350 | 6,500 | 12:18 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.11. | SMAIO appoints Matthieu Ville as chief commercial officer | 3 | Investing.com | ||
| S.M.A.I.O SA Aktie jetzt für 0€ handeln | |||||
| 24.11. | SMAIO Appoints Matthieu Ville as Chief Commercial Officer to Accelerate Commercialization and Strengthen Its Leadership in Spinal Realignment | 222 | Business Wire | Matthieu Ville brings over 15 years of experience in medical marketing in the United States.
Regulatory News:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics- Euronext Growth... ► Artikel lesen | |
| 03.11. | DALLAS - Dr. Tenner Guillaume joins SMAIO's US scientific advisory board | 3 | Investing.com | ||
| 03.11. | SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States | 201 | Business Wire | Appointment of Dr. Tenner Guillaume, Orthopaedic spine surgeon who specializes in spinal deformity at Gillette Children's Hospital (St. Paul, Minnesota). SMAIO's US scientific advisory board... ► Artikel lesen | |
| 22.10. | SMAIO Signs a New Distribution Agreement for Its Open Platform KEOPS-4ME With Orthofix in the U.S. | 376 | Business Wire | Orthofix is a global medical technology company focused on healing musculoskeletal pathologies The distribution arrangement is part of SMAIO's collaborative strategy aimed at deploying... ► Artikel lesen | |
| 17.10. | SMAIO H1 Sales Increase | 1 | RTTNews | ||
| 14.10. | SMAIO Announces Strong First-Half 2025 Results and Robust Growth in Business Activity in the Third Quarter of 2025 | 233 | Business Wire | Strong sales growth in H1 2025: +126% to €5.0 million
Increase in gross margin in H1 2025 to 85% vs. 64% in H1 2024
Significant improvement in EBITDA (+96%) reaching break-even (vs.... ► Artikel lesen | |
| 24.09. | SMAIO Signs the First Major Distribution Agreement for Its Open Platform KEOPS-4ME with Highridge Medical in the U.S. | 317 | Business Wire | Highridge Medical is one of the world's largest privately held spine companies The partnership represents a key milestone in further expanding SMAIO's business activity in the U.S. and driving... ► Artikel lesen | |
| 16.07. | SMAIO Announces Significant Sales Increase in H1 2025 | 333 | Business Wire | Sales H1 2025: +126% to €5 million Acceleration of business activity in the United States (+360% to €3.8 million):
H1 2025 sales1 higher than full-year 2024 sales
More than... ► Artikel lesen | |
| 12.05. | SMAIO Announces the Finalization of a €2.5 Million Fund-Raising, Consisting of a €1.5 Million Capital Increase and a €1 Million Convertible Bond Issue | 385 | Business Wire | The transaction was fully subscribed by NextStage AM, in accordance with the terms previously communicated
Regulatory News:
This press release may not be published, distributed or disseminated... ► Artikel lesen | |
| 15.04. | SMAIO Announces a €2.5 Million Fund-Raising, Consisting of a €1.5 Million Capital Increase and a €1 Million Convertible Bond Issue | 556 | Business Wire | Regulatory News:
This press release may not be published, distributed or disseminated, directly or indirectly, in the United States of America or Canada, Australia, Japan or South Africa.
SMAIO... ► Artikel lesen | |
| 15.04. | SMAIO Announces Consolidated Results for 2024 and Record Sales Performance in Q1 2025 | 425 | Business Wire | Sharp increase in sales, up +114%1 to €5.5 million in 2024 and +140% to €2.5 million in Q1 2025
Improvement in the margin rate on implant sales to 79% in 2024, vs. 71% at the end of 2023... ► Artikel lesen | |
| 28.02. | SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States | 503 | Business Wire | Appointment of Dr. Donald J. Blaskiewicz, neurosurgeon at St. Luke's Clinic in Boise (Idaho) SMAIO's U.S. scientific advisory board now includes three North American surgeons, and is set... ► Artikel lesen | |
| 27.01. | SMAIO Provides Update on Its Partnership With NuVasive and Confirms Its Strategic Focus on the U.S. Market | 324 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics Euronext Growth Paris, ISIN: FR0014005I80 Ticker: ALSMA), a French-American player specialized in complex spine... ► Artikel lesen | |
| 21.01. | SMAIO Announces 2024 Sales of €5.5m, More Than Half of Which Generated in the United States | 552 | Business Wire | Implant sales growth in excess of 100%, thanks to a strategic focus on the US market, driving strong revenue growth which is now mainly generated in the United States Establishment of the Group's... ► Artikel lesen | |
| 06.01. | SMAIO: 2025 Financial Calendar | 380 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics Euronext Growth Paris ISIN: FR0014005I80 Ticker: ALSMA, PEA-PME eligible), a French player specialized in complex... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDLINE | 40,450 | 0,00 % | Aktien New York: Nasdaq schwach nach starkem Jahr - Medline-Börsengang im Blick | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch erneut nachgegeben. Die Wall Street und vor allem die technologielastige Nasdaq zollten ihrem starken Lauf im Jahr 2025 weiter Tribut. Sorgen über... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 35,590 | 0,00 % | BrightSpring upgraded at KeyBanc on specialty pharmacy and EBITDA prospects | ||
| HEARTBEAM | 3,060 | 0,00 % | Heartbeam stock is a buy, this analyst says | ||
| PROGYNY | 26,010 | 0,00 % | Progyny, Inc. - 8-K, Current Report | ||
| ALIGNMENT HEALTHCARE | 20,550 | 0,00 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,490 | -0,34 % | BERNSTEIN RESEARCH stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Siemens Healthineers mit "Outperform" und einem Kursziel von 52,90 Euro in die Bewertung wieder aufgenommen. Nach einem für die... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,190 | -0,27 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| BETA BIONICS | 29,200 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| GENEDX | 135,46 | 0,00 % | GeneDx and Guardant Health named as BTIG's top picks for 2026 | ||
| FRESENIUS | 47,840 | +0,13 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Fresenius mit einem Kursziel von 53,60 Euro auf "Overweight" belassen. Die Veranstaltung mit dem Biopharma-Management der Bad... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 33,780 | 0,00 % | UBS stuft Procept BioRobotics mit "Buy" ein - Wachstum bei Systemauslastung als Treiber | ||
| RXSIGHT | 12,620 | 0,00 % | Pre-market Movers: Basel Medical Group, SOBR Safe, ProKidney, RxSight, Mustang Bio | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green Basel Medical Group Ltd (BMGL) is up over 88% at... ► Artikel lesen | |
| NUTEX HEALTH | 159,17 | 0,00 % | Nutex Health, Inc.: Nutex Health Responds To Short Seller Report | HOUSTON, Nov. 26, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), is aware of a short seller report issued on November... ► Artikel lesen | |
| CLEARPOINT NEURO | 13,550 | 0,00 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Completes Acquisition of IRRAS | Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 6,915 | +0,51 % | LifeStance Health Group, Inc.: LifeStance Reports Third Quarter 2025 Results | SCOTTSDALE, Ariz., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen |
S.M.A.I.O SA gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,100 (-1,56 %) liegt der Kurs bei 6,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu S.M.A.I.O SA finden Sie auf Wallstreet Online.